Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0AUICZ
ADC Name
HuM25-vcMMAE-DAR4
Synonyms
HuM25 vcMMAE-DAR4; huM25 vcMMAE-DAR4
   Click to Show/Hide
Organization
AbbVie, Inc.
Drug Status
Investigative
Indication
In total 2 Indication(s)
Breast cancer [ICD11:2C60-2C65]
Investigative
Non-small cell lung cancer [ICD11:2C25]
Investigative
Drug-to-Antibody Ratio
4
Structure
Antibody Name
HuM25
  Antibody Info 
Antigen Name
Leucine-rich repeat-containing protein 15 (LRRC15)
  Antigen Info 
Payload Name
Monomethyl auristatin E
  Payload Info 
Therapeutic Target
Microtubule (MT)
  Target Info 
Linker Name
Mc-Val-Cit-PABC
  Linker Info 
Conjugate Type
Random conjugation through reduced inter-chain cysteines.
Combination Type
Vedotin
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 3 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Tumor Growth Inhibition value (TGI) 
11
%
HCC827 ER1 cells
Lung adenocarcinoma
Tumor Growth Inhibition value (TGI) 
59.49
%
SUM190PT cells
Breast inflammatory carcinoma
Tumor Growth Inhibition value (TGI) 
84.03
%
EBC-1 cells
Lung squamous cell carcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 3 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) 11.00% (Day 26) High LRRC15 expression (LRRC15+++; IHC 3+)
Method Description
LRRC15 expression on stromal cells asassessed by IHC in an untreated xenograft tumor of 200-800 mm in volume, representative for eachxenograft model. In vivo activity of huM25-vcMMAE-DAR4 (10 mg/kg) was demonstrated in HCC-827-ER xenografts.
In Vivo Model HCC-827-ER CDX model
In Vitro Model Lung adenocarcinoma HCC827 ER1 cells CVCL_EJ07
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) 59.49% (Day 60) High LRRC15 expression (LRRC15+++; IHC 3+)
Method Description
LRRC15 expression on stromal cells asassessed by IHC in an untreated xenograft tumor of 200-800 mm in volume, representative for eachxenograft model. In vivo activity of huM25-vcMMAE-DAR4 (3 mg/kg) was demonstrated in SUM190PT xenografts.
In Vivo Model SUM190PT CDX model
In Vitro Model Breast inflammatory carcinoma SUM190PT cells CVCL_3423
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) 84.03% (Day 21) High LRRC15 expression (LRRC15+++; IHC 3+)
Method Description
LRRC15 expression on stromal cells asassessed by IHC in an untreated xenograft tumor of 200-800 mm in volume, representative for eachxenograft model. In vivo activity of huM25-vcMMAE-DAR4 (3 mg/kg) was demonstrated in EBC-1 xenografts.
In Vivo Model EBC-1 CDX model
In Vitro Model Lung squamous cell carcinoma EBC-1 cells CVCL_2891
References
Ref 1 Anti-huLRRC15 antibody drug conjugates and methods for their use. 2017-06-08

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.